Home/Pipeline/IVL-001

IVL-001

Metabolic Disorders

DiscoveryActive

Key Facts

Indication

Metabolic Disorders

Phase

Discovery

Status

Active

Company

InVirtuoLabs

About InVirtuoLabs

InVirtuoLabs is a private, pre-clinical stage biotech leveraging a proprietary AI and simulation platform to accelerate drug discovery. The company operates a hybrid business model, developing its own internal pipeline of drug candidates while also engaging in co-development partnerships with pharmaceutical companies. With a seasoned leadership team and recognition from Swiss innovation programs, InVirtuoLabs aims to reduce the time, cost, and failure rates associated with traditional drug development.

View full company profile

Therapeutic Areas

Metabolic Disorders Neurological Disorders Pulmonary Vascular Disorders

Other Metabolic Disorders Drugs

Drug	Company	Phase	Status
Novel GLP-1 Receptor Agonist	lupin	Pre-clinical/Clinical	Licensed (Gan & Lee)
Undisclosed Metabolic Program	Kallyope	Discovery	Active
Metabolic Disorders Program	Seragon Biosciences	Pre-clinical	Active
PPARγ Program	Micar Innovation	Discovery	Active
Pancreas-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
AmorphOX GLP-1	Orexo	Preclinical	Active
Amylin Program	Orion Biotechnology	Discovery	Active
Not specifically disclosed on public website	Taisho Pharmaceutical	Various	Active
TLC590	Taiwan Liposome Company	Phase 2	Active